Prevalence and features of fatty liver detected by physical examination in Guangzhou

Table 1 Prevalence of dysmetabolic diseases and biochemical abnormalities in the total study population n (%)

	Patients examined	Positive patients
Hyperlipidemia	2715	1035 (38.1)
Fatty liver	2605	677 (26.0)
Increased ALT and/or AST levels	3393	405 (11.9)
Gallstone	2605	296 (11.4)
HBsAg	2244	198 (8.8)
Hyperglycemia	2767	203 (7.3)
Hypertension	2938	210 (7.3)
Hyperuricemia	2700	167 (6.2)
Increased Scr levels	2150	10 (6.2)

HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine.

Table 2 Age and sex distribution of overall fatty liver prevalence

Age (yr)	All patients	Patients with fatty liver	Overall prevalence	Prevalence in males	Prevalence in females	χ2	P value
18-19	17	1	5.80%	7.10%	0.00%	-	-
20-29	1055	55	5.20%	6.40%	2.30%	7.47	0.006
30-39	1003	206	20.50%	26.70%	8.70%	44.80	< 0.001
40-49	799	212	26.50%	34.50%	16.80%	31.78	< 0.001
50-59	331	123	37.20%	35.90%	39.00%	0.32	0.569
60-69	147	58	39.50%	37.80%	42.10%	0.27	0.601
≥ 70	81	22	27.10%	24.50%	32.10%	0.54	0.464
Total	2605	677	26.00%	32.50%	15.30%	95.18	< 0.001

Table 3 Prevalence of dysmetabolic diseases and biochemical abnormalities in the 677 patients diagnosed with fatty liver n (%)

	Patients examined	Positive patients
Increased ALT and/or AST levels	676	199 (29.4)
Hypertriglyceridemia	635	197 (31.0)
Mixed type hyperlipidemia	635	135 (21.3)
Hypercholesterolemia	635	92 (14.5)
Hyperglycemia	640	116 (18.1)
Hypertension	636	102 (16.0)
Gallstone	677	97 (14.4)
Hyperuricemia	627	87 (13.9)
HBsAg	506	39 (7.7)
Increased Scr levels	507	3 (0.6)

HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine.

Table 4 Sex distribution of prevalence of dysmetabolic diseases and biochemical abnormalities in the 430 subjects with fatty liver n (%)

	All patients	Male patients	Female patients	χ2	P value
Increased ALT and/or AST levels	129 (30.0)	113 (32.6)	16 (19.3)	5.63	0.018
Hypertriglyceridemia	135 (31.4)	125 (36.0)	10 (12.0)	17.87	< 0.001
Mixed type hyperlipidemia	90 (20.9)	65 (18.7)	25 (30.1)	5.25	0.022
Hypercholesterolemia	53 (12.3)	33 (9.5)	20 (24.1)	13.19	< 0.001
Hyperglycemia	76 (17.6)	59 (17.0)	17 (20.5)	0.56	0.455
Hypertension	69 (16.0)	53 (15.3)	16 (19.3)	0.80	0.372
Hyperuricemia	66 (15.3)	60 (17.3)	6 (7.2)	5.22	0.022
Gallstone	62 (14.4)	50 (14.4)	12 (14.4)	0.00	0.991
HBsAg	34 (7.9)	27 (7.9)	7 (7.9)	0.04	0.843
Increased Scr levels	3 (0.7)	3 (0.9)	0 (0.0)	-	-

HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine.

Table 5 Distribution of prevalence of risk factors in patients with and without fatty liver

	Patients with fatty liver (n = 430)		Patients without fatty liver (n = 495)		χ2	P value
	All patients	Prevalence	All patients	Prevalence
Hypertriglyceridemia	135	31.40%	45	9.10%	73.04	< 0.001
Mixed type hyperlipidemia	90	20.90%	33	6.70%	40.61	< 0.001
Hypercholesterolemia	53	12.30%	95	19.20%	8.07	0.004
Hyperglycemia	76	17.70%	25	5.00%	37.70	< 0.001
Hypertension	69	16.00%	32	6.50%	21.72	< 0.001
Hyperuricemia	66	15.30%	14	2.80%	45.66	< 0.001